Jiang, Vivian Changying
Liu, Yang
Jordan, Alexa
Leeming, Angela
McIntosh, Joseph
Huang, Shengjian
Zhang, Rongjia
Cai, Qingsong
Chen, Zhihong
Li, Yijing
Che, Yuxuan
Nie, Lei
Karlsson, Ingrid
Mårtensson, Linda
Kovacek, Mathilda
Teige, Ingrid
Frendéus, Björn
Wang, Michael http://orcid.org/0000-0001-9748-5486
Article History
Received: 23 December 2021
Accepted: 21 March 2022
First Online: 11 April 2022
Declarations
:
: The patient samples were collected from peripheral blood, bone marrow or apheresis after obtaining informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.
: Not applicable.
: M.W. has a grant from BioInvent and philanthropy from Steve and Nancy Fox Cancer Research Fund. I.K, L.M., M.K., I.T. and B.F. are fulltime employed by BioInvent. M.W. is a consultant for: InnoCare, Loxo Oncology, Juno, Oncternal, CStone, AstraZeneca, Janssen, VelosBio, Pharmacyclics, Genentech, Bayer Healthcare, DTRM Biopharma; received research Funding from: Pharmacyclics, Janssen, AstraZeneca, Celgene, Loxo Oncology, Kite Pharma, Juno, BioInvent, VelosBio, Acerta Pharma, Oncternal, Verastem, Molecular Templates, Lilly, Innocare; received honoraria from: Janssen, Acerta Pharma, OMI, Physicians Education Resources, Dava Oncology, CAHON, Hebei Cancer Prevention Federation, Clinical Care Options, Mumbai Hematology Group, Anticancer Association, Newbridge Pharmaceuticals, Chinese Medical Association, Beijing Medical Award Foundation. All other authors declare no competing financial interests.